2 of 5 unlisted pharmas struggling with SG&A/sales ratio higher than 40%

2 of 5 unlisted pharmaceutical companies reportedly have the ratio of SG&A(selling, general and administrative) expenses to sales higher than 40%.

Yakup Shinmoon(www.yakup.com) analyzed 2017 audit reports that 82 unlisted pharmaceutical companies submitted to the Financial Supervisory Service, and the analysis result showed that their SG&A/sales ratio was 34.9% on average. The ratio was increa...